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RESEARCH INTO CONTEXT 
 
Evidence before this study 
Knee replacement is a common and mostly effective intervention for improving pain and disability associated 
with advanced knee joint disease such as osteoarthritis. Despite the high success rates, some knee 
replacements require revision surgery which is associated with higher costs and worse outcomes than the 
primary surgery. In a recent study published by our group in The Lancet, pooled analysis of registry data 
showed that 82% of total knee replacements and 72% of unicompartmental knee replacements last over 25 
years. This study did not evaluate the revision rates following a first revision. In order for both patients and 
their treating surgeons to make informed choices and decisions and health systems to plan and allocate 
resources appropriately, it is important to know treatment outcomes over the life of the patient following 
primary knee replacement, particularly in terms of the risk of revision and subsequent re-revision. We 
searched MEDLINE and Embase from inception to 19 October 2020 and the “Cited Reference Search” function 
in Web of Science, for long-term observational cohort studies and systematic reviews and meta-analyses of 
these studies that have reported on the risk of revision and subsequent re-revision following primary knee 
replacement. We used search terms related to the population (e.g., “primary knee replacement”) and 
outcome (e.g., “revision”, “re-revision”, “survival”, “failure”). Our search was not restricted by language. We 
also evaluated all studies included in our previous study. We identified several relevant studies with long-
term follow-up, but none reported the risk of subsequent re-revisions following the second revision surgery. 
The majority were based on small studies that retrospectively evaluated patients with first-time revision total 
knee replacement and their subsequent risk of re-revision.  No study was identified to have specifically 
evaluated the risk of subsequent re-revisions following the first and second revisions after primary knee 
replacement. 
Added value of this study 
To our knowledge, this is the first observational analysis to attempt to describe the overall treatment 
pathway of patients following primary knee replacement, by determining the probability of revision and 
subsequent re-revisions following the primary surgery. Using data from the National Joint Registry, the largest 
arthroplasty registry in the world, Kaplan-Meier estimates were used to describe the cumulative probability 
of revision following knee replacement in all cases where a link was identified between a known primary 
operation and subsequent revision(s). A total of 33,292 revision knee replacements were linked with the 
primary surgery. Findings showed that 20% of first revisions are revised within 13 years, 20% of second 
revisions are revised within 5 years and 20% of third revisions are revised within 3 years. The risk of multiple 
revision episodes was higher in males and younger patients, and the shorter the time between revision 
episodes, the higher the likelihood of subsequent revision.  
Implications of all the available evidence 
With the aging population and a projected increase in knee replacements, the burden associated with 
revisions will rise proportionately. It appears that though knee replacements are effective for improving pain 
and function and usually last a remarkably long time, if they are revised, successive revisions are progressively 
and markedly less successful. To optimise patient outcomes and reduce high healthcare costs, prosthetic 
combinations that have been shown to have a good chance of lasting a lifetime, or low revision rates at longer 
periods of follow up, should be considered during primary knee replacement, especially for males and 
younger patients who are at higher risk of undergoing subsequent revision(s). Furthermore, the clinical 
decision to conduct a knee replacement is a complex process and should be individualised, tailored to each 




Knee replacements are common and effective operations but patients that undergo this intervention 
are at risk of needing subsequent costly and often complex revision surgery with poorer outcomes 
than primary surgery. The treatment pathway over the life of the patient in terms of risk of revision 
and re-revision(s) is poorly described. We aim to provide detailed information on the longevity of 
revision surgery. 
Methods 
This was a retrospective observational registry-based study of the National Joint Registry. Kaplan-
Meier estimates were used to determine the cumulative probability of revision and subsequent re-
revision(s) following primary knee replacement. Analyses were stratified by age and gender and the 
influence of time from first to second revision on the risk of further revision was explored. 
Findings 
There were 33,292 revision knee replacements with a linked primary episode. Revision rates of 
revision knee replacements were higher in males and younger patients. 19·9% of revisions were 
revised again within 13 years, 20·7% of second revisions were revised again within 5 years and 20·7% 
of third revisions were revised again within 3 years. A shorter time between revision episodes was 
associated with earlier subsequent revision.  
Interpretation 
Males and younger patients are at higher risk of multiple revisions. Patients who undergo a revision 
have steadily increasing risk of further revision the more procedures they undergo, and each 
subsequent revision lasts for approximately half the time of the previous one. 
Funding 
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are those of the author(s) and not necessarily those of the NIHR or the Department of Health and 
Social Care. This study was also supported by funding from Healthcare Quality Improvement 
Partnership and the National Joint Registry. Posts of authors of this work are part funded by a grant 
from the National Joint Registry to conduct statistical analysis for the National Joint Registry. AS was 
funded by a Medical Research Council Strategic Skills Fellowship MR/L01226X/1.  
Introduction 
Knee replacements are very common and a mostly effective intervention for improving pain and 
disability associated with advanced knee joint disease such as osteoarthritis. The lifetime risk of 
undergoing knee replacement is on average one in six for women and one in ten for men.1,2 Studies 
have demonstrated the marked improvement in pain and function within 6 months of surgery3 and 
that knee replacement is highly cost effective.4 Over 100,000 are performed annually in England and 
Wales.5 Rates of primary knee replacement are predicted to increase by 673% between 2005 and 
2030 in the USA,6 117% in England and Wales between 2012 and 20307 and 43% in Germany 
between 2020 and 2050.8 These estimates rely on projections for change in population, 
demographics and that similar increase in use of knee replacement observed in the past will persist 
in the future. Similar patterns are predicted for other types of joint replacement such as hip6,7 and 
shoulder.9 
A recent meta-analysis published in The Lancet has shown that 82% of total knee replacements and 
72% of unicompartmental knee replacements last over 25 years.10 Despite high success rate, some 
knee replacements require revision surgery which is associated with higher costs and worse 
outcomes than the primary surgery. Knee replacements are most commonly revised for aseptic 
loosening / lysis (Prosthesis-time incidence rate (PTIR) per 1,000 years: 1.32, infection (PTIR 0.92), 
pain (PTIR 0.80)  and progressive arthritis (PTIR 0.74).11 Infection of a knee replacement is the most 
common cause for a revision within a year (PTIR 1.81) but becomes less common the longer a 
prosthetic knee is in place (PTIR 0.49 at 5-7 years since primary operation). In contrast aseptic 
loosening and lysis are relatively uncommon in the early period following a revision (PTIR 0.65 for a 
revision within a year), becoming more prominent after one year (E.g. PTIR 1.22 at 5-7 years since 
primary operation).11  
The lifetime risk of revision for patients over the age of 70 at the time of primary knee replacement 
is 5% but these rates are as high as 35% for young males.12 Many knee replacements will therefore 
be revised in the lifetime of the recipient. This resulted in 6,708 revision knee replacements being 
performed in England and Wales in 2019.5 Rates of revision knee replacement are predicted to 
increase by 601% in the USA between 2005 and 20306 and they were observed to increase by 106% 
between 1991 and 201013. Rates are predicted to increase by 332% in England and Wales between 
2012 and 2030,7 having increased by 138% between 2009 and 2019,5 and are predicted to increase 
by 90% in Germany between 2020 and 2050.8 Revision knee replacements are considerably more 
expensive and result in worse function and pain than primary knee replacements.14 
Revision surgery is expensive with worse outcomes and higher complication rates than primary knee 
replacement.15 In order for patients to make informed choices before embarking on joint 
replacement they need to understand the entire patient pathway from intervention to death. To our 
knowledge, no study has specifically evaluated the risk of subsequent re-revisions following the first 
and second revisions after primary knee replacement. Using data from the largest arthroplasty 
database in the world we aimed to ascertain how long revision knee replacements last and how long 





In this retrospective observational registry-based study we analysed data from the National Joint 
Registry (NJR). We collected data on knee arthroplasty revision procedures gathered in the NJR from 
hospitals in England and Wales, since its inception in April 2003 through to the end of December 
2018. A data quality audit in 2017/18 showed over 96% capture of primary knee data and 
approximately 92% capture of revision knee replacements.5 Full details on the specifics of NJR data 
capture and Minimum Data Set forms can be viewed on the NJR website.16 
 
Procedures 
The NJR knee data was prepared for this analysis in the same manner as described in the NJR 2019 
Annual Report.11 In short, the data were cleaned by removing records with missing information, 
removing duplicate procedures, and removing records where we were unable to ascertain a logical 
sequence of revision procedures. The cleaning process (see Figure 1) left us with the same sample of 
procedures as seen in part 3.4 of the 2019 annual report.11   
The NJR data contained details of the operation date and procedure type. Revisions in the NJR are 
defined as any procedure where an implant is added, modified or removed.2 Revision procedures in 
the NJR are classified as single-stage (where the complete revision procedure is performed during 
one surgical episode), stage one of two-stage or stage two of two-stage revisions (where a complete 
revision procedure is performed during at least two separate surgical episodes). Debridement and 
implant retention (DAIR) with or without modular exchange were included as single-stage 
procedures. From these were derived our revision episodes. We assumed single stage and DAIR as 
distinct episodes. In the case of two stage revision, where a 2nd stage revision was recorded within 
365 days of a 1st stage revision procedure, this was considered to be a single distinct revision 
episode. This allowed multiple stage one of two-stage procedures to occur before triggering a new 
episode, as long as the complete first record of a 1st stage revision procedure was followed within 
365 days by a 2nd stage revision procedure. Therefore, if a 1st stage revision was not followed up by a 
2nd stage revision within 365 days the next occurrence of a 1st stage revision was classified as a new 
revision episode. From this we could ascertain the date of the first revision (second prosthetic knee) 
and the dates of the beginning of any subsequent revision episodes potentially forming a second, 
third and fourth revision (third, fourth and fifth prosthetic knees, respectively). The NJR data also 
contained details on gender, age at procedure, and the American Society of Anesthesiologists (ASA) 
grade at procedure. These are described in table 1. Date of death was provided by the Office of 
National Statistics, if the National Health Service number was traceable, and was linked prior to the 
researchers receiving the NJR data.  
We also derived a variable to describe the time interval between the first revision and second 
revision. This was categorised into less than 1 year, between 1 and 3 years, between 3 and 5 years, 
and greater than 5 years.  
 
Statistical analysis 
We used Kaplan-Meier (KM) estimates to describe the cumulative probability of revision knee 
replacement in all cases where we could find a link between a known primary operation and 
subsequent revision(s) of the same side knee (left or right). The link to an associated primary allowed 
us to be sure of the sequence of events and therefore correctly identify the first revision procedure. 
Subsequently, any revision procedures without an associated primary were excluded from the 
analysis as we were not able to ascertain their place in the chain of events. All data were censored at 
date of death or at the end of the study period (31st December 2018). We had three strands to our 
analysis: KM estimates of the survivorship of the first revision, the second revision (a.k.a. re-revision) 
and the third revision (a.k.a. 2nd re-revision). For each of these strands we produced KM estimates 
with 95% confidence intervals, stratified by age (grouped as 55, 55-59, 60-64, 65-69, 70-74, 75-79 
and 80+ years old) and gender. We also calculated the KM estimates of the survivorship of the 
second revision stratified by the time interval between first and second revision.  
Kaplan-Meier estimates and confidence intervals can become less reliable when the numbers at risk 
become low. Thus, consistent with the reporting in the NJR annual reports, we have highlighted (in 
blue italics) any estimate where there are less than 250 procedures at risk at any given time point. 
All analyses were performed using Stata SE, version 15.1. 
 
Sensitivity analyses 
In this study, the exposure of interest is revision knee replacement. We have explored the revision 
trajectories of that first (second prosthetic knee) and subsequent revisions. The definition of first 
revision knee replacement includes revision of total and unicompartmental knee replacements. We 
therefore performed two sensitivity analyses, utilising the primary analysis restricted to revision of 
1) primary total knee replacement and 2) primary unicondylar knee replacements. There were 
insufficient procedures to include a third group of primary patellofemoral procedures undergoing 
revision. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. KD, AS, MRW and AWB had full access to all the data in the 
study and all authors had the final responsibility for the decision to submit for publication. 
  
Results 
The 2019 NJR annual report cohort consisted of 1,193,830 primary knee replacements. In this cohort 
1,162,349 (97.4%) of the primary procedures listed Osteoarthritis (OA) as a primary cause, with 
1,148,855 (96.2%) stating OA as the sole reason for primary.11 Between 1st April 2003 and 31st 
December 2018, the NJR recorded 75,881 revision knee replacements. Of these 33,292 (43·9%) were 
the first documented revision, with an associated primary in the data. This analysis focusses on 
those 33,292 revisions. There were 42,589 (56.1%) revision procedures with no associated primary in 
the data. Out of the revisions with an associated primary, 3,575 (10·7%) of the first revisions were 
subsequently re-revised (2nd revision), with 574 (1·7%) going on to have a third revision. During 
cleaning of the NJR data, prior to obtaining the 33,292 1st revisions, a small number of observations 
were lost due to missing or unverifiable data (N=229 (0.02%)), thus loss to follow is assumed to be 
negligible.  
Table 1 shows the demographics of patients in the cohort as well as the types of revision they 
underwent. There were 28,003 (84·1%) first revisions that were single stage, but only 2,394 (67%) of 
second revisions and 353 (61·5%) of third revisions were single stage, thus indicating the increased 
complexity and increased likelihood of undergoing a two-stage revision during subsequent 
revision(s). The co-morbidity profile of patients also progressively worsened with 25,284 (76%) of 
first-time revision patients classified as ASA Grade 1 or 2, but 2,437 (68·2%) of second revisions and 
only 355 (61·9%) of third revisions. 
Figure 2 and table 2 show that 19·9% (95% CI 18·3-21·5%) of first revisions (second prosthetic knees) 
were performed within 13 years. Revision rates are higher in males than females (at 10 years: 20·0% 
(95% CI 19·0-21·0%) vs 14·8% (95% CI 13·9-15·6%)) and higher in younger patients (at 10 years in 
females under 55 years of age: 21·0% (95% CI 18·7-23·5%) vs females 75-79 years of age: 8·3% (95% 
CI 6·8-10·2%)). 
Figure 2 shows that 20·7% (95% CI 19·1-22·4) of second revisions (third prosthetic knees) were 
performed within 5 years. 
 
Figure 3 shows that 20·7% (95% CI 17·1-24·9) of third revisions (fourth prosthetic knees) were 
performed within 3 years. 
 
Figure 3 shows that time from second to third revision is associated with time between first and 
second revision. 9·5% (95%CI 7·9% - 11·4%) of first revisions that were revised within 1 year are re-
revised (second revision) within a year and 20·2% (95% CI 17·8% - 23·0%) within 3 years, whilst first 
revisions that last 5 years or more have only a 3·6% (95% CI 2·1% - 6·3%) risk of second revision at 1 
year and 9·8% (95% CI 6·5% - 14·7%) at 3 years. 
The most common reasons for the first revision (replacing the 1st prosthetic knee) were Aseptic 
loosening / Lysis (N=9,010 (27.1%)), Infection (N=6,310 (19.0%)) and Pain (N=5,452 (16.4%)). Further 
details regarding reasons for revision of the first revision, and second revision, can be seen in the 
supplemental material.  
 
Sensitivity analyses 
Revision rates appeared marginally better following a unicondylar primary, compared to a total 
primary (see supplemental material), but the same general trend as seen in the original analysis 
persisted. That is approximately 20% revision at 13 years for the second prosthetic knee and 
approximately 20% revision at 5 years for the third prosthetic knee. There was not enough data to 




Previously we have shown that if a patient undergoes a primary total knee replacement, there is 
approximately a 20% chance that the knee will be revised within 25 years. If they undergo a primary 
unicompartmental knee replacement, the chance of revision is approximately 30% within 25 years.10 
In this study we have shown that if the primary knee undergoes a first revision to a second 
prosthetic knee, there is a 20% chance that this second knee will need replacing within 13 years 
requiring a second revision (implantation of a third prosthetic knee). The second revision has a 20% 
chance of needing a third revision within 5 years (a fourth prosthetic knee) which in turn has a 20% 
chance of undergoing a fourth revision (fifth prosthetic knee) within 3 years. Furthermore, the 
longer the primary prosthetic knee lasts, the longer the first revision (second prosthetic knee) is 
likely to last, while the risk of needing further revision is higher in males and younger patients. 
The evidence that we present is consistent with previous literature suggesting that the survivorship 
of a revision total knee replacement (second prosthetic knee) is approximately 80% at 10 years,17-22 
but highlights the increased risk of further revision and morbidity for patients undergoing multiple 
revisions and for those that undergo revision at shorter time intervals. There is a focus in national 
quality improvement programmes on ensuring optimisation of the primary procedure in order to 
reduce the risk of complications and to minimise costs.23 The data we present here reinforces the 
need for such programmes given the high burden created by undergoing revision knee replacement, 
particularly if this happens early. The risk of needing to undergo further revision is substantially 
higher following revision knee replacement than it is following a primary knee replacement.19,22 
Previous work has also shown that complication rates are higher, readmission rates are higher and 
patient reported outcomes are much worse after revision knee replacement than primary knee 
replacement.13,15,24-26 Our data shows that there are a higher proportion of patients undergoing two 
stage revision procedures at subsequent revision episodes reflecting the increased complexity and 
the requirement for multiple stage procedures which patients prefer to avoid.27 This finding is 
consistent with data from the USA and New Zealand showing high proportions of further revisions 
being due to infection following a first revision TKR.18,28 
Patients and surgeons thus need to understand that even though knee replacements are excellent at 
improving pain and function and usually last a remarkably long time, if they are revised, successive 
replacements (revision procedures) are progressively and markedly less successful. We should thus 
make every effort to aim for a strategy of one replacement to last a lifetime to optimise patient 
outcome, reduce the treatment burden on patients and to reduce the high costs associated with 
performing revision knee replacements. Detailed work has been undertaken as to which prosthetic 
combinations for primary arthroplasty have a proven track record in different ages in both 
genders.29,30 5 Arthroplasty registers provide an ideal tool to constantly update and expand this 
information. Decision aid tools can assist in helping patients and clinicians make informed choices 
around primary joint replacement31,32 highlighting risks to groups at higher risk of poor outcomes 
such as male and young patients as demonstrated in this work and previous studies.18,33 
There are several limitations to the work presented here. The exposure of interest is revision knee 
replacement and as such we have grouped different types of primary procedures in the cohort that 
underwent revision. We have performed sensitivity analyses to explore whether this is reasonable, 
and the results are reassuring, demonstrating similar patterns. We present a composite of all 
different types of knee brand, fixations and constraints used at the primary and revision procedures 
and it is conceivable that the revision rates may vary between these groups. In this setting, we have 
treated undergoing a revision, or further subsequent revision, as the exposure of interest as we 
believe this will have the greatest impact on risk of undergoing further revision, rather than implant 
variables that may be constrained by the presentation, indication, bone loss, soft tissue and host 
factors.  
Understanding the causal relationship between successful re-revision and demographic 
characteristics such as age, gender and comorbidities is complex. As patients age their comorbidity 
burden tends to increase and similarly, the longer a prosthetic implant is in situ, the less frequently 
implants are re-revised. Females appear to have a reduced risk of re-revision, however the extent to 
which this is mediated by the length of time the primary and first revision is in situ is less clear. 
Further multi-state analyses are required to understand the causal mechanism underpinning re-
revision from a life-course perspective. A further limitation is that it is likely that specific reasons for 
revising a knee may have a greater or lesser impact on subsequent revision. Despite the large 
dataset the sample for each reason for revision become very small as we progress through the 
sequence of multiple revisions, thereby estimates from these groups may become less precise as 
group sizes decrease. Subdivision into different indications for revision (of which, multiple options 
can be present or selected in the Minimum Dataset forms for the NJR)16 and revision constructs 
would result in even smaller group sizes that would rapidly decline over the sequence of multiple 
revision procedures. Furthermore, it is not clear how generalisable the results from this study are to 
other population around the world. However, the overall revision burden reported by other groups 
including the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) 
and the Swedish Knee Arthroplasty Registry (SKAR) illustrate broadly similar patterns of first revision 
burden to data captured by the NJR and therefore we do not feel that results are likely to be 
substantially different.34,35 Given the scarcity of revision and re-revision we believe large 
observational cohorts, as generated by national registers, will likely be the only feasible source of 
data to conduct analysis of re-revision and understand it risks. Whilst the limitations of prospective 
observational data are well known we see no other feasible way of conducting such studies and 
accordingly results may be suffer from residual confounding and bias. 
 
Conclusion 
In order to decide whether to undergo intervention, patients need the best possible information 
regarding their individual risk of needing to undergo further intervention in the future. We have 
highlighted that males and younger patients need to be made aware that they are at higher risk of 
multiple revisions. We have previously shown that approximately 20% of knee replacements will last 
for 25 years,10 here we show that approximately 20% of first revision will likely last 13 years 
compared to 5 years for second revision and 3 years for third revisions. Patients should also be 
counselled that if they do undergo revision, they are more likely to need a revision after this than 
they were after a primary and that the period that subsequent revisions last approximately halves 
each time a knee is revised. 
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Figure 1: Patient population and exclusions 
 
Total number of knee 
revision procedures
N=75,881
First recorded knee revision 
procedure
N=63,194
Knee procedures that are not 
the first recorded revision 
procedure
N=12,687
Total number of first recorded 
revision procedures with an 
associated primary procedure
N=33,292
First recorded revision 
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associated primary procedure
N=29,902
Total number of cleaned knee 
procedures in the 2019 NJR data
N=1,269,711
Subsequently revised (2nd revision)
N=3,575
Subsequently revised (3rd revision)
N=574
Figure 2: Kaplan-Meier estimates of cumulative revision in those with linked primary knee 




Figure 3: Kaplan-Meier estimates of cumulative probability of third revision by time between first 





Table 1: Demographics of the study population 
  Revisions Second revisions Third revisions 
  Male Female All Male Female All Male Female All 
Totals (N, %) 15,080 (45.3) 18,212 (54.7) 33,292 (100.0) 1,919 (53.7) 1,656 (46.3) 3,575 (100.0) 339 (59.1) 235 (40.9) 574 (100.0) 
                              
Average age in years (SD) 67 (9.7) 68 (10.3) 67 (10.0) 66 (9.7) 67 (10.0) 66 (9.8) 66 (9.6) 65 (9.9) 66 (9.7) 
Age group (N, %)                              
<55 2,611 (17.3) 3,456 (19.0) 6,067 (18.2) 435 (22.7) 396 (23.9) 831 (23.2) 91 (26.8) 67 (28.5) 158 (27.5) 
55-64 5,380 (35.7) 5,953 (32.7) 11,333 (34.0) 730 (38.0) 583 (35.2) 1,313 (36.7) 128 (37.8) 84 (35.7) 212 (36.9) 
65-74 5,108 (33.9) 5,853 (32.1) 10,961 (32.9) 596 (31.1) 495 (29.9) 1,091 (30.5) 97 (28.6) 73 (31.1) 170 (29.6) 
75+ 1,981 (13.1) 2,950 (16.2) 4,931 (14.8) 158 (8.2) 182 (11.0) 340 (9.5) 23 (6.8) 11 (4.7) 34 (5.9) 
Average ASA grade (SD) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 
ASA grade (N, %)                              
ASA grade 1 1,457 (9.7) 1,370 (7.5) 2,827 (8.5) 160 (8.3) 90 (5.4) 250 (7.0) 24 (7.1) 12 (5.1) 36 (6.3) 
ASA grade 2 9,982 (66.2) 12,475 (68.5) 22,457 (67.5) 1,155 (60.2) 1,032 (62.3) 2,187 (61.2) 194 (57.2) 125 (53.2) 319 (55.6) 
ASA grade 3 3,497 (23.2) 4,218 (23.2) 7,715 (23.2) 578 (30.1) 511 (30.9) 1,089 (30.5) 119 (35.1) 93 (39.6) 212 (36.9) 
ASA grade 4 143 (0.9) 148 (0.8) 291 (0.9) 26 (1.4) 23 (1.4) 49 (1.4) 2 (0.6) 5 (2.1) 7 (1.2) 
ASA grade 5 1 (0.0) 1 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Revision procedure (N, %)                              
Amputation 5 (0.0) 8 (0.0) 13 (0.0) 5 (0.3) 7 (0.4) 12 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Conversion to Arthrodesis 24 (0.2) 23 (0.1) 47 (0.1) 23 (1.2) 17 (1.0) 40 (1.1) 4 (1.2) 6 (2.6) 10 (1.7) 
DAIR 93 (0.6) 64 (0.4) 157 (0.5) 19 (1.0) 14 (0.8) 33 (0.9) 6 (1.8) 4 (1.7) 10 (1.7) 
Single stage 12,122 (80.4) 15,881 (87.2) 28,003 (84.1) 1,231 (64.1) 1,163 (70.2) 2,394 (67.0) 202 (59.6) 151 (64.3) 353 (61.5) 
Stage 1 of 2 2,074 (13.8) 1,641 (9.0) 3,715 (11.2) 418 (21.8) 276 (16.7) 694 (19.4) 74 (21.8) 48 (20.4) 122 (21.3) 
Stage 2 of 2 762 (5.1) 595 (3.3) 1,357 (4.1) 223 (11.6) 179 (10.8) 402 (11.2) 53 (15.6) 26 (11.1) 79 (13.8) 
 
Table 2: Kaplan-Meier estimates of cumulative failure of first revision  
 
    Time since first revision 
Age group 
(years) n 1 year 3 years 5 years 7 years 10 years 13 years 15 years 
All cases 33,292 3.59 (3.39-3.80) 9.51 (9.17-9.87) 12.64 (12.22-13.07) 14.82 (14.33-15.32) 17.11 (16.47-17.77) 19.86 (18.34-21.47)   
Females 18,212 3.01 (2.76-3.27) 7.89 (7.47-8.34) 10.92 (10.38-11.47) 12.70 (12.09-13.35) 14.75 (13.94-15.60) 16.62 (14.92-18.49) 17.60 (15.16-20.37) 
F <55 3,456 3.04 (2.51-3.69) 8.64 (7.65-9.74) 13.91 (12.54-15.41) 17.07 (15.42-18.87) 20.96 (18.65-23.51) 24.55 (18.14-32.73)  
F 55-59y 2,773 2.71 (2.15-3.41) 8.97 (7.85-10.23) 12.18 (10.81-13.72) 15.40 (13.70-17.29) 18.34 (16.06-20.90) 18.77 (16.37-21.47)  
F 60-64y 3,180 2.55 (2.05-3.18) 7.84 (6.87-8.95) 10.65 (9.44-12.00) 12.30 (10.93-13.83) 13.56 (11.94-15.39) 16.63 (13.16-20.91) 16.63 (13.16-20.91) 
F 65-69y 3,203 3.64 (3.02-4.37) 8.40 (7.40-9.53) 11.41 (10.17-12.78) 12.55 (11.19-14.06) 14.57 (12.81-16.54) 15.22 (13.12-17.62)  
F 70-74y 2,650 2.71 (2.14-3.42) 6.71 (5.74-7.84) 8.71 (7.54-10.06) 9.47 (8.19-10.93) 10.56 (9.02-12.35) 12.39 (9.02-16.90)  
F 75-79y 1,853 3.21 (2.48-4.15) 5.67 (4.63-6.93) 7.15 (5.91-8.65) 7.66 (6.31-9.29) 8.31 (6.75-10.22) 8.31 (6.75-10.22)  
F 80+ 1,097 3.47 (2.50-4.80) 7.91 (6.28-9.95) 8.29 (6.59-10.40) 8.29 (6.59-10.40) 8.29 (6.59-10.40)   
Males 15,080 4.30 (3.97-4.64) 11.47 (10.92-12.05) 14.72 (14.07-15.41) 17.36 (16.59-18.17) 19.96 (18.96-21.01) 23.60 (21.15-26.29)  
M <55 2,611 5.04 (4.24-5.98) 15.03 (13.58-16.63) 19.02 (17.31-20.87) 23.07 (21.01-25.31) 26.62 (23.94-29.54) 28.84 (24.88-33.28)  
M 55-59y 2,342 3.49 (2.80-4.34) 11.83 (10.45-13.37) 16.00 (14.32-17.84) 18.35 (16.45-20.44) 22.22 (19.64-25.09) 26.77 (22.26-31.99)  
M 60-64y 3,038 4.44 (3.74-5.26) 11.51 (10.32-12.82) 15.07 (13.65-16.62) 18.30 (16.60-20.16) 19.96 (17.99-22.12) 20.65 (18.32-23.23)  
M 65-69y 2,869 4.12 (3.43-4.94) 11.10 (9.89-12.46) 13.64 (12.23-15.20) 15.39 (13.80-17.15) 18.09 (15.96-20.47) 24.83 (18.28-33.21)  
M 70-74y 2,239 4.72 (3.90-5.72) 10.60 (9.29-12.08) 13.48 (11.93-15.21) 15.84 (14.00-17.90) 17.45 (15.18-20.02) 17.45 (15.18-20.02)  
M 75-79y 1,330 3.61 (2.70-4.80) 7.79 (6.36-9.53) 10.15 (8.35-12.31) 11.86 (9.75-14.39) 13.63 (10.58-17.47) 19.80 (10.55-35.38)  
M 80+ 651 4.24 (2.91-6.17) 7.48 (5.53-10.08) 8.60 (6.37-11.55) 9.44 (6.84-12.97) 10.76 (7.44-15.42) 10.76 (7.44-15.42)  
Blue italics signify that fewer than 250 cases remained at risk at these time points 
 
 
Table 3: Kaplan-Meier estimates of cumulative failure of second revision  
 
    Time since previous revision 
Age group 
(years) n 1 year 3 years 5 years 7 years 10 years 13 years 
All cases 3,575 6.29 (5.51-7.17) 15.85 (14.54-17.26) 20.66 (19.07-22.35) 23.03 (21.24-24.94) 25.74 (23.32-28.37)   
Females 1,656 5.20 (4.19-6.44) 13.85 (12.07-15.86) 19.20 (16.94-21.73) 20.47 (18.04-23.18) 23.33 (19.80-27.36) 25.11 (20.47-30.59) 
F <55 396 4.68 (2.93-7.42) 15.37 (11.72-20.01) 24.33 (19.25-30.46) 25.11 (19.90-31.41) 34.05 (24.27-46.39)  
F 55-59y 298 7.02 (4.53-10.80) 18.71 (14.21-24.42) 22.96 (17.71-29.47) 26.36 (20.27-33.87) 26.36 (20.27-33.87) 26.36 (20.27-33.87) 
F 60-64y 285 4.96 (2.91-8.39) 11.67 (8.12-16.64) 13.01 (9.15-18.32) 15.76 (10.86-22.57) 15.76 (10.86-22.57) 15.76 (10.86-22.57) 
F 65-69y 303 7.16 (4.68-10.89) 16.30 (12.22-21.58) 20.31 (15.47-26.40) 20.31 (15.47-26.40) 24.10 (16.49-34.44)  
F 70-74y 192 5.07 (2.67-9.53) 10.01 (6.21-15.93) 19.89 (13.29-29.18) 19.89 (13.29-29.18) 19.89 (13.29-29.18)  
F 75-79y 110 0 5.99 (2.54-13.82) 11.27 (5.67-21.74) 11.27 (5.67-21.74) 11.27 (5.67-21.74)  
F 80+ 72 1.41 (0.20-9.58) 5.79 (1.86-17.24) 5.79 (1.86-17.24) 5.79 (1.86-17.24) 5.79 (1.86-17.24)  
Males 1,919 7.22 (6.11-8.52) 17.55 (15.72-19.56) 21.86 (19.72-24.20) 25.15 (22.64-27.88) 27.79 (24.53-31.39) 27.79 (24.53-31.39) 
M <55 435 8.37 (6.05-11.52) 21.29 (17.36-25.98) 25.07 (20.60-30.30) 28.97 (23.70-35.11) 31.81 (24.79-40.24) 31.81 (24.79-40.24) 
M 55-59y 327 6.81 (4.49-10.26) 16.26 (12.25-21.42) 18.88 (14.36-24.60) 24.84 (18.70-32.56) 33.43 (23.74-45.73) 33.43 (23.74-45.73) 
M 60-64y 403 6.30 (4.27-9.25) 16.66 (12.99-21.24) 23.02 (18.47-28.48) 25.21 (20.24-31.14) 26.54 (21.13-33.03) 26.54 (21.13-33.03) 
M 65-69y 334 6.97 (4.60-10.51) 16.75 (12.73-21.87) 22.18 (17.25-28.26) 24.68 (19.27-31.29) 24.68 (19.27-31.29)  
M 70-74y 262 6.13 (3.74-9.96) 15.22 (11.09-20.71) 19.00 (14.04-25.44) 20.56 (15.03-27.76) 20.56 (15.03-27.76)  
M 75-79y 112 9.09 (4.82-16.78) 19.38 (12.15-30.10) 21.30 (13.54-32.57) 25.67 (15.71-40.25) 25.67 (15.71-40.25)  
M 80+ 46 11.53 (4.97-25.52) 11.53 (4.97-25.52) 11.53 (4.97-25.52) 11.53 (4.97-25.52)   










Table 4 KM estimates of cumulative failure of third revision  
 
    Time since previous revision 
Age group 
(years) n 1 year 3 years 5 years 7 years 10 years 
All cases 574 7.52 (5.55-10.16) 20.70 (17.14-24.88) 29.44 (24.60-34.99) 32.14 (26.68-38.40)   
Females 235 5.99 (3.44-10.32) 17.91 (12.88-24.60) 25.25 (18.38-34.12) 28.13 (19.97-38.71) 28.13 (19.97-38.71) 
F <55 67 3.34 (0.84-12.69) 17.37 (9.37-30.91) 21.12 (11.58-36.71) 21.12 (11.58-36.71) 21.12 (11.58-36.71) 
F 55-59y 53 4.61 (1.17-17.21) 19.38 (9.65-36.69) 37.62 (20.03-63.08) 37.62 (20.03-63.08) 37.62 (20.03-63.08) 
F 60-64y 31 16.96 (6.71-39.19) 23.35 (10.18-48.23) 32.93 (15.11-62.23) 32.93 (15.11-62.23)  
F 65-69y 49 9.16 (3.53-22.65) 21.09 (11.02-38.13) 25.73 (13.86-44.74) 35.01 (18.05-60.66) 35.01 (18.05-60.66) 
F 70-74y 24 0 11.46 (2.99-38.61) 11.46 (2.99-38.61) 11.46 (2.99-38.61)  
F 75-79y 8 0 0 0   
F 80+ 3        
Males 339 8.58 (5.96-12.27) 22.55 (17.90-28.19) 31.86 (25.65-39.15) 34.30 (27.55-42.17) 36.93 (28.99-46.24) 
M <55 91 9.26 (4.74-17.69) 28.59 (19.41-40.87) 35.29 (23.88-50.05) 39.33 (26.63-55.37) 39.33 (26.63-55.37) 
M 55-59y 55 15.77 (8.21-29.09) 26.06 (15.53-41.72) 32.64 (20.35-49.65) 32.64 (20.35-49.65)  
M 60-64y 73 8.86 (4.07-18.70) 21.19 (12.80-33.90) 32.57 (20.13-49.88) 32.57 (20.13-49.88) 32.57 (20.13-49.88) 
M 65-69y 57 4.07 (1.02-15.48) 14.65 (6.69-30.39) 37.30 (20.27-61.80) 37.30 (20.27-61.80) 37.30 (20.27-61.80) 
M 70-74y 40 5.26 (1.34-19.44) 26.37 (13.94-46.45) 26.37 (13.94-46.45) 41.10 (18.93-73.68) 41.10 (18.93-73.68) 
M 75-79y 18 5.88 (0.85-34.98) 5.88 (0.85-34.98) 17.65 (4.32-57.43) 17.65 (4.32-57.43)  
M 80+ 5 0 0 0 0  
Blue italics signify that fewer than 250 cases remained at risk at these time points 
 
  
 
 
